Doravirine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Doravirine
Doravirine structure.svg
Clinical data
Trade namesPifeltro
SynonymsMK-1439
Routes of
administration
Oral[1]
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
ECHA InfoCard100.234.454 Edit this at Wikidata
Chemical and physical data
FormulaC17H11ClF3N5O3
Molar mass425.75 g/mol
3D model (JSmol)

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).[2]

References[edit]

  1. ^ Collins, Simon; Horn, Tim. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
  2. ^ FDA Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients